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1. Introduction
Pancreatic cancer remains one of the most lethal solid organ tumors with a poor 
5-year survival rate despite current oncological advances. The poor prognosis is 
related mostly to the late clinical manifestation. Patients usually are diagnosed in an 
unresectable stage when metastases are present [1]. 85% of the cases of pancreatic 
cancer are adenocarcinomas [2]. Pancreatic neuroendocrine tumors (NETs) are rare 
tumors with highly variable behaviors from nearly benign to extremely aggressive 
[3]. The early and proper diagnosis of pancreatic cancer is of a great importance for 
the improvement of the ovSerall prognosis. Symptoms are nonspecific and include 
progressive weight loss, anorexia, abdominal pain and jaundice. The recent advances 
and increasing sensitivity of the diagnostic techniques such as multi-detector-row 
computed tomography (MDCT), magnetic resonance imaging (MRI), positron 
emission tomography (PET) CT and endoscopic ultrasound (EUS) are promising for 
the early pancreatic cancer detection, staging and differentiation from other pancre-
atic diseases [4]. The resectability of the tumor depends on the possible infiltration 
of vessels and lymph nodes as well as distant metastases. The pancreastic cancer 
is resectable, borderline resectable, locally advanced or metastatic. Prognosis and 
treatment depend on the stage of pancreatic cancer as treatment strategies include 
surgery, ablation, chemotherapy, radiation therapy, and palliative care [5].
2. Challenging the pancreatic cancer
Less than 20% of the patients with pancreatic cancer are diagnosed in an early 
resectable stage, achieving a negative resection margin (R0) and a significant 
survival improvement [5, 6]. An adjuvant chemotherapy is mostly recommended 
after pancreatic resection [5]. A recent metaanalysis highlights the beneficial effect 
of neoadjuvant therapy in borderline and locally advanced pancreatic tumors, 
associated with a decreased tumor-stage, higher rates of R0-resections, lower rates 
of lymphnode invasion, decreased frequency of lymphatic vessel and perineural 
invasion [7]. After biopsy confirmation, chemotherapy is the treatment of choice 
for unresectable pancreatic cancer. Different regiments such as gemcitabine /
erlotinib, FOLFIRINOX, gemcitabine /NAB-paclitaxel, gemcitabine/capecitabine, 
and capecitabine/oxaliplatin (XELOX) are recommended according to the patient’s 
performance status [8]. Palliative care relieves symptoms and ensures optimal 
quality of life [5]. According to the complications of pancreatic cancer, patients 
might need endoscopic placement of stents for treating biliary obstruction, pancre-
atic enzyme replacement therapy for pancreatic exocrine insufficiency, insulin for 
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treating diabetes mellitus, gastrojejunostomy, enteral stent or PEG tube in case of 
gastric outlet obstruction, as well as pain management and nutritive support [8–11]. 
Increasing is the interest on the tumor microenvironment and the arising potential 
future treatment option. Current clinical trials investigate promising treatment 
strategies for advanced pancreatic cancer such as stroma modifying drugs, platinum 
chemotherapy, RAS-directed therapies, immunotherapy with pembrolizumab, 
immune checkpoint inhibitor combinations or natural killer cells [12–14].
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